Biogen (BIIB) Long-Term Deferred Tax (2017 - 2026)
Biogen (BIIB) posted quarterly Long-Term Deferred Tax of $202.1 million for Q2 2026, down 38.92% year-over-year from $330.9 million in Q2 2025, and down 15.16% quarter-over-quarter from $238.2 million in Q1 2026.
Biogen (BIIB) Long-Term Deferred Tax (2017 - 2026) Analysis & Trends
Biogen's Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $202.1 million for Q2 2026.
- In Q2 2026, Long-Term Deferred Tax fell 38.92% year-over-year to $202.1 million; the TTM figure through Jun 2026 stood at $202.1 million (down 38.92% YoY), while the FY2025 annual figure was $292.5 million, down 9.78% from the prior year.
- Long-Term Deferred Tax for Q2 2026 stood at $202.1 million, down from $238.2 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $1.3 billion in Q1 2022, with the low at $202.1 million in Q2 2026.
- The 5-year median for Long-Term Deferred Tax is $921.8 million (2023), against an average of $785.2 million.
- The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax increased 0.19% in 2022, then slumped 67.75% in 2025.
- Biogen's Long-Term Deferred Tax stood at $1.2 billion in 2022, then fell by 24.28% to $928.6 million in 2023, then sank by 65.09% to $324.2 million in 2024, then dropped by 9.78% to $292.5 million in 2025, then slumped by 30.91% to $202.1 million in 2026.
- Business Quant data shows BIIB's Long-Term Deferred Tax at $202.1 million in Q2 2026, $238.2 million in Q1 2026, and $292.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 202.10 Mn |
| Mar 31, 2026 | 238.20 Mn |
| Dec 31, 2025 | 292.50 Mn |
| Sep 30, 2025 | 312.40 Mn |
| Jun 30, 2025 | 330.90 Mn |
| Mar 31, 2025 | 307.50 Mn |
| Dec 31, 2024 | 324.20 Mn |
| Sep 30, 2024 | 968.70 Mn |
| Jun 30, 2024 | 915.10 Mn |
| Mar 31, 2024 | 898.30 Mn |
| Dec 31, 2023 | 928.60 Mn |
| Sep 30, 2023 | 1.07 Bn |
| Jun 30, 2023 | 1.21 Bn |
| Mar 31, 2023 | 1.21 Bn |
| Dec 31, 2022 | 1.23 Bn |
| Sep 30, 2022 | 1.17 Bn |
| Jun 30, 2022 | 1.24 Bn |
| Mar 31, 2022 | 1.29 Bn |
| Dec 31, 2021 | 1.42 Bn |
| Sep 30, 2021 | 1.81 Bn |